A Phase 1 interventional study of Fruquintinib (HMPL-013) in Advanced Solid Tumors, Metastatic Colon Cancer and Metastatic Breast Cancer, sponsored by Hutchison Medipharma Limited. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-25.
Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,122 studies in Colonic Neoplasms with a site in United States — 116 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.
Among the 1,122 studies in Colonic Neoplasms with a site in United States, this one is the 256th largest by enrollment of the 864 interventional ones that give a count, is one of 43 that started in 2017, is one of 244 in phase 1, and was the 772nd registered.
2,456 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
Browse Colonic Neoplasms studies →116 of the 1,122 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
Solstice Oncology, Inc. · Sites in United States, Belgium, Italy and 3 more countries
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
Guardant Health, Inc. · Sites in United States
Ages 45–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 352 · Phase 2 341 · Phase 3 87 · Phase 4 10
First in 1981; this study’s year is marked. 43 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 50 across the 864 interventional studies, 220 across the 181 observational. Of the 839 that completed or were terminated, 241 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 1,122 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hutchison Medipharma Limited, one of the names counted as HUTCHMED. Under that name alone:
Hutchison Medipharma Limited is the lead sponsor of 68 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.
HUTCHMED has 2 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
60 of the studies in Colonic Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03803553Phase 3Massachusetts General HospitalIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | 2026-12 |
| NCT06191185University of California, San FranciscoIMProving Adherence to Colonoscopy Through Teams and Technology | 2026-11-27 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
| NCT00582621Memorial Sloan Kettering Cancer CenterAscertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | 2026-12 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,122 studies in Colonic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.
The study was an open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors. The study consisted of two phases:
Study was conducted at 9 sites in the United States.
Key Inclusion Criteria:
Dose Escalation Phase:
Dose Expansion Phase:
Key Exclusion Criteria:
Patients will be excluded from the study, if any of the following criteria is met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 mg of Fruquintinib (HMPL-013), capsule taken orally, daily, 3 weeks on, 1 week off
Drug: Fruquintinib (HMPL-013)
5 mg of Fruquintinib (HMPL-013), capsule taken orally, daily, 3 weeks on, 1 week off
Drug: Fruquintinib (HMPL-013)
5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with advanced solid tumors of any type.
Drug: Fruquintinib (HMPL-013)
5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
Drug: Fruquintinib (HMPL-013)
5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
Drug: Fruquintinib (HMPL-013)
5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
Drug: Fruquintinib (HMPL-013)
5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
Drug: Fruquintinib (HMPL-013)
Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
Also known as: HMPL-013
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs)
Dose-limiting toxicity was defined as: Any Grade 4 non-hematologic toxicity; Any Grade 3 non-hematologic toxicity related to study drug except for nausea/vomiting, diarrhea, constipation, hypertension, and electrolyte imbalances downgraded within 3-days with appropriate supportive treatment; Grade 4 neutropenia lasting \>3 days; Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \<1.0\*10\^9 per liter \[/L\] with a single temperature of greater than (\>) 38.3 degree centigrade (°C) or a sustained temperature of greater than or equal to (\>=) 38°C for more than 1 hour); Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with bleeding; Dose interruption for \>14 days due to toxicity.
Time frame: Cycle 1 (cycle length equal to [=] 28 days)
Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A serious adverse event (SAE) was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).
Time frame: From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months)
Dose Expansion Phase: Progression Free Survival (PFS) Rate
PFS was defined as time from date of first dosing until date of an objective disease progression (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death due to any cause, whichever comes first. PFS was determined using all data until last evaluable visit prior to or on date of: (i) radiographic PD per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy other than study drugs, whichever was earlier. PFS rate was defined as probability of being disease progression free at selected timepoints such as 16 weeks and was calculated using Brookmeyer-Crowley method based on PFS events observed up to 29 months. PD:at least 20 percent (%) increase in sum of diameters of target lesions, taking as reference smallest sum on study, including baseline; an absolute increase of at least 5 millimeter (mm) in sum of diameters of target lesions; and appearance of one or more new lesions.
Time frame: From the first dose of study drug to disease progression, or death, whichever occurred first (i.e., up to 29 months)
Dose Escalation and Expansion Phase: Maximum Observed Plasma Concentration (Cmax) of Fruquintinib
Cmax of fruquintinib was reported.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Fruquintinib
Tmax of fruquintinib over a dosing intervals were reported.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Minimum Observed Plasma Concentration (Cmin) of Fruquintinib
Cmin of fruquintinib was reported.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Time to Reach Minimum Observed Plasma Concentration (Tmin) of Fruquintinib
Tmin of fruquintinib was reported.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Fruquintinib
AUC0-24 of fruquintinib was reported.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Apparent Clearance at Steady State (CL/Fss) of Fruquintinib
CL/Fss was calculated as Dose/AUC0-t. As planned, CL/Fss was assessed at Cycle 1 Days 14 and 21 after multiple dose administration in Dose Escalation Phase and Cohort A of Dose Expansion Phase; and at Cycle 1 Day 14 for Cohort B, C, D, E of Expansion Phase.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Accumulation Ratio Based on Cmax of Fruquintinib
Accumulation ratio based on Cmax for Cycle 1 Day 14 was calculated as Day 14 Cmax /Day 1 Cmax and for Cycle 1 Day 21 was calculated as Day 21 Cmax /Day 1 Cmax. Accumulation ratio based on Cmax of fruquintinib was reported.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14 and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Accumulation Ratio Based on AUC0-24 Hours of Fruquintinib
Accumulation ratio for Cycle 1 Day 14 was calculated as AUC0-24 at Day 14 divided by AUC0-24h at Day 1, and for Cycle 1 Day 21 was calculated as AUC0-24 at Day 21 divided by AUC0-24 at Day 1. Accumulation ratio based on AUC0-24 of fruquintinib was reported.
Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14 and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Dose Escalation and Expansion Phase: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with objective complete response (CR) or partial response (PR) response per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: From the first dose of study drug until first documentation of best overall response (i.e., up to 29 months)
Dose Escalation and Expansion Phase: Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a best overall response (BOR) of confirmed CR, confirmed PR or stable disease (SD) (for 7 weeks) per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study \[this might include the baseline sum\]).
Time frame: From the first dose of study drug until first documentation of best overall response (i.e., up to 29 months)
Dose Escalation and Expansion Phase: Duration of Response (DoR)
DoR was defined as the time (in months) from the date of the first objective response (CR or PR) until the date of the documented progression or of death, whichever comes first. DoR was only analyzed for participants whose best overall response (BOR) was either CR or PR. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). DoR was calculated using the Kaplan-Meier method.
Time frame: From the date of the first objective response (CR or PR) until the date of the documented disease progression or of death, whichever comes first (i.e., up to 29 months)
Dose Escalation and Expansion Phase: Progression Free Survival (PFS)
PFS was defined as the time (in months) from date of first dosing until the date of an objective disease progression as per RECIST version 1.1 or death due to any cause, whichever comes first. PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of (i) disease progression as defined by RECIST version 1.1 or death; or (ii) withdrawal of consent; or (iii) receiving subsequent anti-cancer therapy, whichever is earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). PFS was calculated using the Kaplan-Meier method.
Time frame: From date of first dose until the date of an objective disease progression or death due to any cause, whichever comes first (i.e., up to 29 months)
Dose Escalation and Expansion Phase: Overall Survival (OS)
OS was defined as the time interval (in months) between the first dose date and the date of death (any cause). OS was calculated using the Kaplan-Meier method.
Time frame: From first dose date to the date of death (due to any cause) (i.e., up to 29 months)
Dose Escalation and Expansion Phase: Percent Change From Baseline (PCFB) in Tumor Size
Tumor size was estimated using data on sum of diameters of target lesion. Percentage change in tumor size from baseline was determined for participants with measurable disease at baseline and derived by the percentage change in the sum of the diameters of target lesions (TLs) compared to baseline. Baseline was defined as the last evaluable tumor assessment result obtained prior to the first administration of study medication.
Time frame: Baseline up to 29 months
Dose Expansion Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A SAE was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).
Time frame: From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months)
The study was conducted at 9 study sites in the United States.
| Milestone | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 6 | 41 | 40 | 14 | 14 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 7 | 6 | 41 | 40 | 14 | 14 |
| Withdrew: Death | 3 | 2 | 3 | 30 | 24 | 12 | 12 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Patient withdrew consent and refused to provide follow-up information | 0 | 0 | 0 | 3 | 2 | 1 | 1 |
| Withdrew: Progressive disease | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 3 | 2 | 0 | 1 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 4 | 13 | 0 | 0 |
Dose-limiting toxicity was defined as: Any Grade 4 non-hematologic toxicity; Any Grade 3 non-hematologic toxicity related to study drug except for nausea/vomiting, diarrhea, constipation, hypertension, and electrolyte imbalances downgraded within 3-days with appropriate supportive treatment; Grade 4 neutropenia lasting \>3 days; Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \<1.0\*10\^9 per liter \[/L\] with a single temperature of greater than (\>) 38.3 degree centigrade (°C) or a sustained temperature of greater than or equal to (\>=) 38°C for more than 1 hour); Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with bleeding; Dose interruption for \>14 days due to toxicity.
| Participants | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg |
|---|---|---|
| Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) | 1 | 0 |
TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A serious adverse event (SAE) was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).
| Participants | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg |
|---|---|---|
| Participants with TEAEs | 7 | 7 |
| Participants with serious TEAEs | 3 | 2 |
PFS was defined as time from date of first dosing until date of an objective disease progression (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death due to any cause, whichever comes first. PFS was determined using all data until last evaluable visit prior to or on date of: (i) radiographic PD per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy other than study drugs, whichever was earlier. PFS rate was defined as probability of being disease progression free at selected timepoints such as 16 weeks and was calculated using Brookmeyer-Crowley method based on PFS events observed up to 29 months. PD:at least 20 percent (%) increase in sum of diameters of target lesions, taking as reference smallest sum on study, including baseline; an absolute increase of at least 5 millimeter (mm) in sum of diameters of target lesions; and appearance of one or more new lesions.
| percentage of participants | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|
| Dose Expansion Phase: Progression Free Survival (PFS) Rate | 53.33 (4.68 to 100.00) | 61.04 (45.59 to 76.49) | 55.64 (39.87 to 71.41) | 29.30 (1.91 to 56.70) | 38.46 (12.02 to 64.91) |
Cmax of fruquintinib was reported.
| nanogram per milliliter (ng/mL) | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 52.2 ± 24.2 | 114 ± 27.5 | 96.0 ± 23.0 | 85.2 ± 32.1 | 89.0 ± 43.2 | 104 ± 37.0 | 105 ± 36.5 |
| Cycle 1 Day 14 | 198 ± 9.8 | 403 ± 33.7 | 336 ± 50.9 | 271 ± 26.5 | 293 ± 27.1 | 331 ± 36.1 | 352 ± 23.4 |
| Cycle 1 Day 21 | 205 ± 12.8 | 390 ± 19.1 | 238 ± NA | — | — | — | — |
Tmax of fruquintinib over a dosing intervals were reported.
| hours | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.07 (1.03 to 21.2) | 1.95 (0.917 to 25.0) | 1.96 (1.00 to 13.8) | 2.25 (0.917 to 23.8) | 2.04 (0.983 to 2.04) | 2.00 (1.00 to 18.4) | 2.01 (1.75 to 23.9) |
| Cycle 1 Day 14 | 1.03 (0.967 to 1.92) | 2.00 (1.97 to 7.05) | 1.52 (1.00 to 2.03) | 2.03 (0.00 to 26.1) | 2.00 (0.933 to 7.18) | 1.86 (0.917 to 7.00) | 1.84 (0.933 to 7.00) |
| Cycle 1 Day 21 | 1.83 (0.917 to 1.98) | 2.00 (1.88 to 4.08) | 1.00 (NA to NA) | — | — | — | — |
Cmin of fruquintinib was reported.
| ng/mL | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 14 | 138 ± 28.3 | 281 ± 101 | 251 ± 114 | 193 ± 57.3 | 204 ± 63.2 | 227 ± 98.4 | 249 ± 72.1 |
| Cycle 1 Day 21 | 140 ± 27.0 | 283 ± 81.0 | 182 ± NA | — | — | — | — |
Tmin of fruquintinib was reported.
| hours | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 14 | 0.00 (0.00 to 7.00) | 0.508 (0.00 to 27.8) | 3.57 (0.00 to 7.13) | 0.00 (0.00 to 25.6) | 0.00 (0.00 to 28.2) | 0.00 (0.00 to 23.9) | 0.458 (0.00 to 22.0) |
| Cycle 1 Day 21 | 7.00 (0.00 to 25.6) | 3.54 (0.00 to 24.9) | 7.00 (NA to NA) | — | — | — | — |
AUC0-24 of fruquintinib was reported.
| hour*nanogram per millimeter (h*ng/mL) | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 912 ± 21.5 | 2010 ± 19.2 | 1340 ± 25.6 | 1384 ± 39.0 | 1550 ± 46.5 | 1821 ± 31.5 | 1739 ± 39.8 |
| Cycle 1 Day 14 | 3694 ± 17.1 | 8249 ± 35.2 | 6507 ± 53.7 | 5338 ± 28.9 | 5833 ± 27.3 | 6135 ± 40.1 | 6957 ± 25.1 |
| Cycle 1 Day 21 | 3731 ± 22.5 | 7740 ± 26.7 | 4995 ± NA | — | — | — | — |
CL/Fss was calculated as Dose/AUC0-t. As planned, CL/Fss was assessed at Cycle 1 Days 14 and 21 after multiple dose administration in Dose Escalation Phase and Cohort A of Dose Expansion Phase; and at Cycle 1 Day 14 for Cohort B, C, D, E of Expansion Phase.
| milliliter per minute (mL/min) | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 14 | 14.4 ± 2.90 | 11.1 ± 4.04 | 14.1 ± 7.31 | 16.3 ± 5.16 | 14.8 ± 3.92 | 14.7 ± 7.18 | 12.3 ± 2.80 |
| Cycle 1 Day 21 | 14.1 ± 3.07 | 11.3 ± 2.83 | 17.5 ± NA | — | — | — | — |
Accumulation ratio based on Cmax for Cycle 1 Day 14 was calculated as Day 14 Cmax /Day 1 Cmax and for Cycle 1 Day 21 was calculated as Day 21 Cmax /Day 1 Cmax. Accumulation ratio based on Cmax of fruquintinib was reported.
| ratio | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 14 | 4.06 ± 1.42 | 3.66 ± 1.42 | 3.57 ± 0.232 | 3.32 ± 1.21 | 3.44 ± 1.36 | 3.22 ± 1.38 | 3.40 ± 0.963 |
| Cycle 1 Day 21 | 4.22 ± 1.45 | 3.47 ± 1.22 | 3.40 ± NA | — | — | — | — |
Accumulation ratio for Cycle 1 Day 14 was calculated as AUC0-24 at Day 14 divided by AUC0-24h at Day 1, and for Cycle 1 Day 21 was calculated as AUC0-24 at Day 21 divided by AUC0-24 at Day 1. Accumulation ratio based on AUC0-24 of fruquintinib was reported.
| ratio | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 14 | 4.24 ± 1.21 | 4.19 ± 1.19 | 4.04 ± NA | 3.87 ± 1.22 | 4.38 ± 3.08 | 3.73 ± 1.51 | 4.37 ± 1.70 |
| Cycle 1 Day 21 | 4.36 ± 1.53 | 3.90 ± 0.964 | 4.43 ± NA | — | — | — | — |
ORR was defined as the percentage of participants with objective complete response (CR) or partial response (PR) response per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| percentage of participants | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Phase: Objective Response Rate (ORR) | 16.7 (0.42 to 64.12) | 14.3 (0.36 to 57.87) | 0.0 (0.00 to 45.93) | 2.4 (0.06 to 12.86) | 5.1 (0.63 to 17.32) | 0.0 (0.00 to 30.85) | 0.0 (0.00 to 24.71) |
DCR was defined as the percentage of participants with a best overall response (BOR) of confirmed CR, confirmed PR or stable disease (SD) (for 7 weeks) per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study \[this might include the baseline sum\]).
| percentage of participants | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Phase: Disease Control Rate (DCR) | 66.7 (22.28 to 95.67) | 71.4 (29.04 to 96.33) | 66.7 (22.28 to 95.67) | 68.3 (51.91 to 81.92) | 59.0 (42.10 to 74.43) | 60.0 (26.24 to 87.84) | 38.5 (13.86 to 68.42) |
DoR was defined as the time (in months) from the date of the first objective response (CR or PR) until the date of the documented progression or of death, whichever comes first. DoR was only analyzed for participants whose best overall response (BOR) was either CR or PR. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). DoR was calculated using the Kaplan-Meier method.
| months | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Phase: Duration of Response (DoR) | 7.56 (NA to NA) | NA (NA to NA) | — | 4.04 (NA to NA) | NA (5.65 to NA) | — | — |
PFS was defined as the time (in months) from date of first dosing until the date of an objective disease progression as per RECIST version 1.1 or death due to any cause, whichever comes first. PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of (i) disease progression as defined by RECIST version 1.1 or death; or (ii) withdrawal of consent; or (iii) receiving subsequent anti-cancer therapy, whichever is earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). PFS was calculated using the Kaplan-Meier method.
| months | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Phase: Progression Free Survival (PFS) | 6.90 (0.56 to NA) | NA (3.65 to NA) | 5.49 (1.77 to NA) | 4.67 (2.76 to 5.32) | 3.75 (2.00 to 5.49) | 2.43 (1.74 to 5.06) | 1.87 (1.15 to 3.94) |
OS was defined as the time interval (in months) between the first dose date and the date of death (any cause). OS was calculated using the Kaplan-Meier method.
| months | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Phase: Overall Survival (OS) | 22.70 (0.56 to NA) | 19.58 (6.05 to NA) | 6.03 (4.24 to NA) | 8.71 (6.57 to 11.47) | 10.64 (5.16 to 19.32) | 12.06 (6.21 to 13.24) | 8.74 (3.78 to 15.93) |
Tumor size was estimated using data on sum of diameters of target lesion. Percentage change in tumor size from baseline was determined for participants with measurable disease at baseline and derived by the percentage change in the sum of the diameters of target lesions (TLs) compared to baseline. Baseline was defined as the last evaluable tumor assessment result obtained prior to the first administration of study medication.
| percent change | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Phase: Percent Change From Baseline (PCFB) in Tumor Size | 5.41 ± NA | -20.70 ± 16.485 | -12.92 ± 25.919 | 7.40 ± 23.713 | 19.23 ± 20.808 | -8.07 ± 8.574 | 9.82 ± 16.824 |
TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A SAE was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).
| Participants | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|
| Participants with TEAEs | 6 | 41 | 39 | 14 | 14 |
| Participants with serious TEAEs | 4 | 19 | 14 | 2 | 4 |
Collected over From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation Phase: Fruquintinib 3 mg | 3/7 (42.9%) | 3/7 (42.9%) | 7/7 (100%) |
| Dose Escalation Phase: Fruquintinib 5 mg | 2/7 (28.6%) | 2/7 (28.6%) | 7/7 (100%) |
| Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | 3/6 (50%) | 4/6 (66.7%) | 6/6 (100%) |
| Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | 30/41 (73.2%) | 19/41 (46.3%) | 41/41 (100%) |
| Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | 25/40 (62.5%) | 14/40 (35%) | 39/40 (97.5%) |
| Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | 12/14 (85.7%) | 2/14 (14.3%) | 14/14 (100%) |
| Dose Expansion Phase, Cohort E: Fruquintinib 5 mg | 12/14 (85.7%) | 4/14 (28.6%) | 14/14 (100%) |
| Event | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/7 | 0/7 | 1/6 | 3/41 | 3/40 | 0/14 | 1/14 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/7 | 0/7 | 1/6 | 1/41 | 0/40 | 0/14 | 0/14 |
| Upper respiratory tract infectionInfections and infestations | 0/7 | 0/7 | 1/6 | 0/41 | 0/40 | 0/14 | 0/14 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/7 | 0/7 | 1/6 | 1/41 | 1/40 | 0/14 | 0/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/7 | 0/7 | 1/6 | 0/41 | 0/40 | 0/14 | 0/14 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/7 | 0/7 | 1/6 | 0/41 | 0/40 | 0/14 | 0/14 |
| Angina pectorisCardiac disorders | 0/7 | 0/7 | 1/6 | 0/41 | 0/40 | 0/14 | 0/14 |
| Acquired oesophageal webGastrointestinal disorders | 1/7 | 0/7 | 0/6 | 0/41 | 0/40 | 0/14 | 0/14 |
| Large intestinal obstructionGastrointestinal disorders | 1/7 | 0/7 | 0/6 | 1/41 | 0/40 | 0/14 | 0/14 |
| Breast cellulitisInfections and infestations | 0/7 | 1/7 | 0/6 | 0/41 | 0/40 | 0/14 | 0/14 |
| Event | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/7 | 3/7 | 5/6 | 17/41 | 5/40 | 5/14 | 4/14 |
| HypertensionVascular disorders | 2/7 | 3/7 | 5/6 | 20/41 | 29/40 | 9/14 | 6/14 |
| ConstipationGastrointestinal disorders | 5/7 | 3/7 | 3/6 | 11/41 | 6/40 | 6/14 | 3/14 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 2/7 | 4/7 | 4/6 | 13/41 | 10/40 | 5/14 | 3/14 |
| NauseaGastrointestinal disorders | 4/7 | 4/7 | 1/6 | 11/41 | 6/40 | 7/14 | 7/14 |
| VomitingGastrointestinal disorders | 4/7 | 4/7 | 3/6 | 7/41 | 3/40 | 2/14 | 4/14 |
| Weight decreasedInvestigations | 2/7 | 4/7 | 0/6 | 9/41 | 4/40 | 1/14 | 3/14 |
| Decreased appetiteMetabolism and nutrition disorders | 2/7 | 4/7 | 2/6 | 14/41 | 10/40 | 4/14 | 2/14 |
| FatigueGeneral disorders | 1/7 | 3/7 | 2/6 | 22/41 | 12/40 | 8/14 | 5/14 |
| HeadacheNervous system disorders | 1/7 | 4/7 | 2/6 | 11/41 | 6/40 | 5/14 | 7/14 |
The safety analysis set (SAS) included all participants who received at least 1 dose of the study drug.
| Age, Continuous(years) | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 61.08 ± 5.566 | 57.72 ± 12.712 | 68.91 ± 8.879 | 58.54 ± 10.182 | 56.94 ± 9.923 | 55.45 ± 13.443 | 50.86 ± 9.152 | 57.45 ± 10.672 |
| Sex: Female, Male(Participants) | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 6 | 3 | 21 | 24 | 14 | 14 | 86 |
| Male | 3 | 1 | 3 | 20 | 16 | 0 | 0 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 | 1 | 0 | 1 | 6 |
| Not Hispanic or Latino | 6 | 6 | 6 | 38 | 39 | 13 | 13 | 121 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Dose Escalation Phase: Fruquintinib 3 mg | Dose Escalation Phase: Fruquintinib 5 mg | Dose Expansion Phase, Cohort A: Fruquintinib 5 mg | Dose Expansion Phase, Cohort B: Fruquintinib 5 mg | Dose Expansion Phase, Cohort C: Fruquintinib 5 mg | Dose Expansion Phase, Cohort D: Fruquintinib 5 mg | Dose Expansion Phase, Cohort E: Fruquintinib 5 mg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 3 | 0 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 4 | 4 | 0 | 4 | 13 |
| White | 7 | 6 | 6 | 33 | 33 | 13 | 9 | 107 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Dec 2022, 60 months.
Results were first posted in Sep 2024, 1 year 9 months after primary completion.
Of 51 industry-sponsored phase 1 interventional studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 60 months is above that.
Counting every sponsor, half of 116 studies reached it within 48 months; a quarter within 32 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HMPL-013
Hutchison Medipharma Limited →